Celeste Rojas

Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1–2 trial

Owen A. O’Connor, Jennifer Kimberly Lue, Ahmed Sawas et al. · The Lancet Oncology · 2017 · 118 citations · Full text

Medicine, Oncology, Pharmacology +16

Phase I Trial of Weekly and Twice-Weekly Bortezomib with Rituximab, Cyclophosphamide, and Prednisone in Relapsed or Refractory Non–Hodgkin Lymphoma

John F. Gerecitano, Carol S. Portlock, Paul A. Hamlin et al. · Clinical Cancer Research · 2011 · 27 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

The Combination of Brentuximab Vedotin (Bv) and Bendamustine (B) Demonstrates Marked Activity in Heavily Treated Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) and Anaplastic Large T-Cell Lymphoma (ALCL): Results of an International Multi Center Phase I/II Experience

Ahmed Sawas, Joseph M. Connors, John Kuruvilla et al. · Blood · 2015 · 13 citations

Medicine, Oncology, Pharmacology +17

A Phase 1/2 Study of Oral 5-Azacitidine and Romidepsin in Patients with Lymphoid Malignancies Reveals Promising Activity in Heavily Pretreated Peripheral T-Cell Lymphoma (PTCL)

Lorenzo Falchi, Jennifer Kimberly Lue, Jennifer E. Amengual et al. · Blood · 2017 · 10 citations

Medicine, Oncology, Pharmacology +5

PL02.06 First-Line Osimertinib + Chemotherapy Versus Osimertinib Monotherapy in EGFRm Advanced NSCLC: FLAURA2 Final Overall Survival

D. Planchard, P.A. Jänne, K. Kobayashi et al. · Journal of Thoracic Oncology · 2025 · 10 citations

Medicine, Oncology, Pharmacology +8